Iwata, Takashi

写真a

Affiliation

School of Medicine, Department of Obstetrics and Gynecology (Gynecology) （Shinanomachi）

Position

Assistant Professor/Senior Assistant Professor
Page Top ▲

Academic Background 【 Display / hide 】

  • 1995

    慶応義塾大学, 医学部, 医学科

    Graduated

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 日本婦人科腫瘍学会婦人科腫瘍専門医

  • 日本臨床細胞学会細胞診専門医

  • 日本がん治療認定医機構がん治療認定医

  • 日本がん治療認定医機構暫定教育医

  • 日本産科婦人科学会専門医

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Obstetrics and gynecology

Page Top ▲

Research Keywords 【 Display / hide 】

  • 婦人科腫瘍の免疫学的特性

  • 子宮頸癌の臨床病理的特徴

  • 子宮頸部での局所免疫応答

Page Top ▲
 

Books 【 Display / hide 】

  • 子宮頚癌治療ガイドライン　２０１７年度版

    Iwata Takashi, 金原出版株式会社, 2017.07

Page Top ▲

Papers 【 Display / hide 】

  • Ancient Evolutionary History of Human Papillomavirus Type 16, 18 and 58 Variants Prevalent Exclusively in Japan

    Tanaka K., Kogure G., Onuki M., Matsumoto K., Iwata T., Aoki D., Kukimoto I.

    Viruses （Viruses)  14 （ 3 ）  2022.03

    　View Summary

    Human papillomavirus (HPV) is a sexually transmitted virus with an approximately 8-kilo base DNA genome, which establishes long-term persistent infection in anogenital tissues. High levels of genetic variations, including viral genotypes and intra-type variants, have been described for HPV genomes, together with geographical differences in the distribution of genotypes and variants. Here, by employing a maximum likelihood method, we performed phylogenetic analyses of the complete genome sequences of HPV16, HPV18 and HPV58 available from GenBank (n = 627, 146 and 157, respectively). We found several characteristic clusters that exclusively contain HPV genomes from Japan: two for HPV16 (sublineages A4 and A5), one for HPV18 (sublineage A1) and two for HPV58 (sublineages A1 and A2). Bayesian phylogenetic analyses of concatenated viral gene sequences showed that divergence of the most recent common ancestor of these Japan-specific clades was estimated to have occurred ~98,000 years before present (YBP) for HPV16 A4, ~39,000 YBP for HPV16 A5, ~38,000 YBP for HPV18 A1, ~26,000 for HPV58 A1 and ~25,000 YBP for HPV58 A2. This estimated timeframe for the divergence of the Japan-specific clades suggests that the introduction of these HPV variants into the Japanese archipelago dates back to at least ~25,000 YBP and provides a scenario of virus co-migration with ancestral Japanese populations from continental Asia during the Upper Paleolithic period.

  • Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program.

    Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, For The Mint Study Group

    Vaccines 10 （ 2 ）  2022.01

  • Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.

    Onuki M, Yamamoto K, Yahata H, Kanao H, Yokota H, Kato H, Shimamoto K, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Watari H, Nakamura K, Ueda A, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Taguchi A, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, MINT Study Group.

    Cancer science  2022.01

    ISSN  1347-9032

  • Transcription factor homeobox d9 drives the malignant phenotype of hpv18-positive cervical cancer cells via binding to the viral early promoter

    Hayashi S., Iwata T., Imagawa R., Sugawara M., Chen G., Tanimoto S., Sugawara Y., Tanaka I., Matsui T., Nishio H., Nakamura M., Katoh Y., Mori S., Kukimoto I., Aoki D.

    Cancers （Cancers)  13 （ 18 ）  2021.09

    　View Summary

    Persistent infections with two types of human papillomaviruses (HPV), HPV16 and HPV18, are the most common cause of cervical cancer (CC). Two viral early genes, E6 and E7, are associated with tumor development, and expressions of E6 and E7 are primarily regulated by a single viral promoter: P97 in HPV16 and P105 in HPV18. We previously demonstrated that the homeobox D9 (HOXD9) transcription factor is responsible for the malignancy of HPV16-positive CC cell lines via binding to the P97 promoter. Here, we investigated whether HOXD9 is also involved in the regulation of the P105 promoter using two HPV18-positive CC cell lines, SKG-I and HeLa. Following the HOXD9 knockdown, cell viability was significantly reduced, and E6 expression was suppressed and was accompanied by increased protein levels of P53, while mRNA levels of TP53 did not change. E7 expression was also downregulated and, while mRNA levels of RB1 and E2F were unchanged, mRNA levels of E2F-target genes, MCM2 and PCNA, were decreased, which indicates that the HOXD9 knockdown downregulates E7 expression, thus leading to an inactivation of E2F and the cell-cycle arrest. Chromatin immunoprecipitation and promoter reporter assays confirmed that HOXD9 is directly associated with the P105 promoter. Collectively, our results reveal that HOXD9 drives the HPV18 early promoter activity to promote proliferation and immortalization of the CC cells.

  • A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis

    Ishikawa M., Shibata T., Iwata T., Nishio S., Takada T., Suzuki S., Horie K., Kudaka W., Kagabu M., Tanikawa M., Kitagawa R., Takekuma M., Kobayashi H., Yaegashi N.

    Gynecologic Oncology （Gynecologic Oncology)  162 （ 2 ） 292 - 298 2021.08

    ISSN  00908258

    　View Summary

    Objective: To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in metastatic or recurrent cervical carcinoma not amenable to curative local therapy. Methods: Patients were randomly assigned to either the cTC or ddTC arm. The cTC regimen was paclitaxel 175 mg/m2 and carboplatin at an area under the curve (AUC) of 5 on day 1. The ddTC regimen was paclitaxel 80 mg/m2 on day 1, 8, 15 and carboplatin at AUC of 5 on day 1. Both cTC and ddTC treatments were repeated every 3 weeks for up to 9 cycles. After bevacizumab was approved in Japan, patients in both arms received bevacizumab 15 mg/kg if not contraindicated. The primary endpoint of phase II part was response rate (RR). If the RR of ddTC+bevacizumab was found to be at least 5% better than to cTC + bevacizumab, the study would proceed to phase III part, which had overall survival as its primary endpoint. Clinical trial information: jRCTs031180007. Results: In total, 122 patients were randomly assigned to either the cTC arm (cTC + bevacizumab: 32; cTC:29) or the ddTC arm (ddTC+bevacizumab: 30; ddTC:31). The RR for patients on cTC + bevacizumab was 67.9%, and for patients on ddTC+bevacizumab 60.7%, cTC: 55.2%, and ddTC: 50.0%. Conclusions: The study did not meet the primary endpoint of phase II portion. Dose-dense, weekly paclitaxel plus carboplatin is not promising for metastatic or recurrent cervical carcinoma.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 明日からできる悪性腫瘍の手術 円錐切除術から準広汎子宮全摘術まで~レーザー蒸散術~

    岩田卓

    OGS NOW basic 7 (メジカルビュー社)   2021.08

    Joint Work, Lead author, Last author, Corresponding author

  • 【婦人科がん機能温存治療のすべて】子宮頸がん　1)子宮頸部円錐切除術

    岩田 卓

    産科と婦人科 ((株)診断と治療社)  88 ( 7 ) 812 - 817 2021.07

    ISSN  0386-9792

    　View Summary

    子宮頸部円錐切除術の対象となる子宮頸部上皮内腫瘍(CIN)3を含む子宮頸部初期病変の多くは、生殖年齢層に発症する。円錐切除術後の妊娠では、早産率が増加するとされており、本手術を施行するにあたっては、その後の妊娠・出産への影響を念頭に、術前の病理診断のみならず、病変の広がり、局在の評価に基づき、切除範囲を決定することが求められる。本稿では、妊孕性温存術を念頭に置いた円錐切除術の手技を紹介するとともに、最近報告された、わが国における円錐切除術後妊娠の転帰について解説する。(著者抄録)

  • 【産婦人科患者説明ガイド-納得・満足を引き出すために】婦人科疾患　(Q1)子宮腟部びらんと言われました.どんな病気ですか?

    岩田 卓

    臨床婦人科産科 ((株)医学書院)  75 ( 4 ) 297 - 298 2021.04

    ISSN  0386-9865

  • 子宮頸癌の治療　子宮頸癌の手術

    岩田 卓

    日本産科婦人科学会雑誌 ((公社)日本産科婦人科学会)  72 ( 12 ) 1688 - 1693 2020.12

    ISSN  0300-9165

  • 咽頭部違和感症を訴える更年期女性に対する、半夏厚朴湯の効果と検討

    大野 あゆみ, 横田 めぐみ, 谷本 慧子, 堀場 裕子, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    日本女性医学学会雑誌 ((一社)日本女性医学学会)  28 ( 1 ) 165 - 165 2020.10

    ISSN  2185-8861

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • Newly developed adoptive cell therapy using autologous tumor-infiltrating lymphocytes in cervical cancer

    Takashi Iwata

    The 7th Biennial Meeting of Asian Society of Gynecologic Oncology (Bankok) , 

    2021.11
    , 

    Symposium, workshop panel (nominated)

  • 当科における悪性腫瘍治療後患者へのホルモン補充療法(HRT)の有用性に関する検討

    谷本 慧子, 横田 めぐみ, 椎名 美希, 大野 あゆみ, 黒田 由香, 吉浜 智子, 千代田 達幸, 増田 健太, 西尾 浩, 仲村 勝, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    第36回女性医学学会学術集会 (大阪) , 

    2021.11

  • 2022028234 子宮頸癌術後患者におけるPHQ-9と更年期症状の関連について

    大野 あゆみ, 横田 めぐみ, 椎名 美季, 谷本 慧子, 西尾 浩, 弟子丸 亮太, 山上 亘, 阪埜 浩司, 岩田 卓, 青木 大輔

    第36回女性医学学会学術集会 (大阪) , 

    2021.11

  • 新型コロナウイルス感染症拡大下における骨粗鬆症治療への影響

    椎名 美季, 横田 めぐみ, 大野 あゆみ, 谷本 慧子, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    第36回女性医学学会学術集会 (大阪) , 

    2021.11

  • 子宮頸部病変における免疫応答の解析と、進行子宮頸癌に対する腫瘍浸潤リンパ球輸注療法

    岩田卓

    第36回生殖免疫学会総会・学術集会 (東京) , 

    2021.10
    , 

    Symposium, workshop panel (nominated)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 腫瘍浸潤リンパ球輸注療法（TIL療法）を実施した子宮頸癌患者の免疫応答解析

    2022.04
    -
    2025.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 基盤研究(B), Principal investigator

  • Development of TIL culture method for tumor infiltrating T cell therapy for cervical cancer

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • Analysis of molecular biological and tumor immunological characteristics of HPV negative cervical adenocarcinoma

    2015.04
    -
    2018.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • MEDICAL PROFESSIONALISM 6

    2022

  • LECTURE SERIES, GYNECOLOGY

    2022

  • MEDICAL PROFESSIONALISM 6

    2021

  • LECTURE SERIES, GYNECOLOGY

    2021

  • LECTURE SERIES, GYNECOLOGY

    2020

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本免疫学会

    　

  • 日本癌学会

    　

  • 日本癌治療学会

    　

  • 日本臨床細胞学会

    　

  • 日本婦人科腫瘍学会

    　

display all >>

Page Top ▲